Cipher Pharmaceuticals Inc.
CPHRF
Get informed when a big investor buys or sells
+ FollowMarket Cap$346.59M
Close$
$29.66
208.3% upside
Current Fair Value
208.3% upsideUndervalued by 208.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $346.59 Million |
|---|---|
| Enterprise Value | $350.38 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.09 |
| Beta | 0.48 |
| Outstanding Shares | 25,399,550 |
Return
| Return on Equity | 21.16% |
|---|---|
| Return on Assets | 18.51% |
| Return on Invested Capital | 13.93% |
Valuation & Multiples
| P/E Ratio | 8.4 |
|---|---|
| PEG | -24.97 |
| Price to Sales | 9.62 |
| Price to Book Ratio | 1.92 |
| Enterprise Value to Revenue | 7.1 |
| Enterprise Value to EBIT | 18.33 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$13.61 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.20
Average shareholder expectationRevenue Estimate
$12.23 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cipher Pharmaceuticals, Inc.
5 employees
CEO: Craig Mull Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. It acquires products that fulfill unmet medical needs, manages the required clin...